GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (XTER:1SXP) » Definitions » Net Income (Discontinued Operations)

Schott Pharma AG KGaA (XTER:1SXP) Net Income (Discontinued Operations) : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Schott Pharma AG KGaA's Net Income (Discontinued Operations) for the three months ended in Dec. 2024 was €0.0 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Schott Pharma AG KGaA Net Income (Discontinued Operations) Historical Data

The historical data trend for Schott Pharma AG KGaA's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Net Income (Discontinued Operations) Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24
Net Income (Discontinued Operations)
- - - - -

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Schott Pharma AG KGaA Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Schott Pharma AG KGaA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (XTER:1SXP) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
XTER:FIE XTER:AFX XTER:GXI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN COO BAX WST NZSE:FPH ALGN SOLV HOLX
Traded in Other Exchanges
SHTPY:USA 1SXP:Italy 1SXPd:UK 1SXP:Austria
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Website
https://www.schott-pharma.com
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.
Executives
Dr. Jens Schulte Supervisory Board
Andreas Reisse Board of Directors
Ann-kristin Erkens Supervisory Board
Dr. Almuth Steinkühler Board of Directors
Dr. Wolfgang Wienand Supervisory Board
Peter Goldschmidt Supervisory Board

Schott Pharma AG KGaA Headlines

No Headlines